AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29650037
Drug: Experimental schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental schedule 2/1 (50 mg daily)
Trial: 29650037
Drug: Standard schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard schedule 4/2 (37.5 mg daily)
Trial: 23263000
Drug: GS-9851 400
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GS-9851 400 mg once daily for 3 days
Trial: 12829988
Drug: Ribavirin (1,000-1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (1,000-1,200 mg daily)
Trial: 10996722
Drug: Chemotherapy (n=20;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (n=20; 1052 lymph nodes)
Trial: 1797498
Drug: Human ultralente
RxNorm normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human ultralente insulin before supper
Trial: 6117537
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg lorazepam
Trial: 21890585
Drug: TPA023 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA023 (2 mg)
Trial: 21890585
Drug: Alcohol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.6 g/L)
Trial: 17475735
Drug: Weekly interpersonal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly interpersonal psychotherapy (IPT)
Trial: 17475735
Drug: Twice-monthly interpersonal
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-monthly interpersonal psychotherapy (IPT)
Trial: 17475735
Drug: Monthly interpersonal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly interpersonal psychotherapy (IPT)
Trial: 17475735
Drug: IPT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPT with selective serotonin reuptake inhibitor (SSRI)
Trial: 15025617
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of bupivacaine and 50 microg of morphine
Trial: 15025617
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of bupivacaine and 25 microg of fentanyl
Trial: 15025617
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of bupivacaine and saline
Trial: 11283120
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m²/day for 5 days every 21 days)
Trial: 11283120
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m² over 3 hours every 21 days)
Trial: 7685226
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium (40-120 mg/day)
Trial: 1474534
Drug: Naproxen (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (1000 mg/day)
Trial: 29772695
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT‐A) injections
Trial: 2254512
Drug: Behavioral Marital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Marital Therapy (BMT) Alone
Trial: 6118980
Drug: Talinolol (cordanum)
RxNorm normalized name: talinolol
DrugBank: Talinolol (DB11770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol (cordanum) administered intravenously and then orally
Trial: 26253746
Drug: e-virtual reality
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-virtual reality exposure therapy (remote sessions)
Trial: 26253746
Drug: traditional virtual
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: traditional virtual reality exposure therapy (in-person sessions)
Trial: 22652990
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid (nonparticulate Celestone)
Trial: 7598235
Drug: Carbonated lidocaine
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbonated lidocaine (20 mL of 1.73% carbonated lidocaine with epinephrine 5 micrograms/mL plus 2 mL of 0.9% NaCl, pH 6.42 +/- 0.04)
Trial: 7598235
Drug: pH adjusted
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH adjusted lidocaine (20 mL of lidocaine with epinephrine 5 micrograms/mL plus 2 mL of 8.4% sodium bicarbonate, pH 6.47 +/- 0.16)
Trial: 7598235
Drug: Lidocaine HCl
RxNorm normalized name: lidocaine HCl
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine HCl (control group, 20 mL of 2% lidocaine with epinephrine 5 micrograms/mL plus 2 mL of NaCl 0.9%, pH 4.58 +/- 0.10)
Trial: 2369808
Drug: Dihydroergotamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (0.5 mg)
Trial: 146524
Drug: Intravenous physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous physostigmine
Trial: 146524
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with oral choline chloride
Trial: 146524
Drug: Single 5-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 5-g dose of choline chloride
Trial: 414267
Drug: Chlorpromazine 75
RxNorm normalized name: chlorproMAZINE 75 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine 75 mg
Trial: 29737796
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme 8371 USP unit of lipase, 3 times daily for 1 month
Trial: 24131304
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg lebrikizumab administered subcutaneously every 4 weeks over 12 weeks (total of four doses)
Trial: 24131304
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously every 4 weeks over 12 weeks (total of four doses)
Trial: 24131304
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg lebrikizumab
Trial: 15604157
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics at home
Trial: 15604157
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics in hospital
Trial: 10191283
Drug: Stanol ester
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanol ester margarine (2 or 3 g/day)
Trial: 8703669
Drug: theophylline +
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: theophylline + 200 mg nefazodone twice daily (every 12h)
Trial: 8703669
Drug: theophylline +
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: theophylline + matching nefazodone placebo capsule twice daily (every 12h)
Trial: 8703669
Drug: theophylline +
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: theophylline + 200 mg nefazodone
Trial: 25532515
Drug: rFSH +
RxNorm normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rFSH + GnRH antagonist (n = 45)
Trial: 23619901
Drug: ICG-augmented diode
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-augmented diode laser therapy (ICG + DL) at a total dose of 4 mg/kg body weight
Trial: 23619901
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) therapy before and after ICG administration (ICG + IPL)
Trial: 19763572
Drug: High-dose HAIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose HAIC (5-FU, 500 mg/m² on days 1-3 and cisplatin, 60 mg/m² on day 2)
Trial: 19763572
Drug: Low-dose HAIC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose HAIC (5-FU, 170 mg/m² and cisplatin, 7 mg/m² on days 1-5)
Trial: 19763572
Drug: High-dose HAIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose HAIC
Trial: 19763572
Drug: Low-dose HAIC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose HAIC
Trial: 18447211
Drug: Needle-pricking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-pricking therapy combined with spinal massage
Trial: 18447211
Drug: Azulfidine (medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azulfidine (medication group)
Trial: 11192138
Drug: Amlodipine (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (once daily, morning or evening)
Trial: 9159299
Drug: Sodium ramping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ramping (linear from 155 mEq/L to 140 mEq/L)
Trial: 9159299
Drug: Standard dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysis (steady dialysate sodium of 140 mEq/L)
Trial: 8439075
Drug: Nebulized L‐Adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized L‐Adrenaline and placebo (IM)
Trial: 8439075
Drug: Nebulized L‐Adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized L‐Adrenaline and dexamethasone (IM)
Trial: 3530030
Drug: Birch pollen
RxNorm normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch pollen preparation (n = 14) with doses up to 1.4 X 10(6) biologic units per day
Trial: 3530030
Drug: Birch pollen
RxNorm normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch pollen preparation (n = 14)
Trial: 27255560
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% plus 8 mg dexamethasone
Trial: 18761784
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg continuously once daily
Trial: 18761784
Drug: Levocetirizine 5
RxNorm normalized name: Levocetirizine 5mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 5 mg on-demand
Trial: 11130294
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (hGH) at a dose of 0.125 U.kg‐1.wk‐1 for four weeks and 0.25 U.kg‐1.wk‐1 thereafter
Trial: 6384817
Drug: 5 X
RxNorm normalized name: PAD,ABDOMINAL 5 X 9 STERILE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 X 10(6) IU of natural alpha interferon daily for 6 months
Trial: 22205314
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (various doses from 0 to 2000 μg/d)
Trial: 22205314
Drug: High-iodine intervention
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-iodine intervention groups (1500-2000 μg)
Trial: 22205314
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg I supplementation
Trial: 22205314
Drug: 500-2000 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-2000 μg I supplementation
Trial: 20150398
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg per day + interferon beta-1a
Trial: 17295573
Drug: Fluoxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine + Cognitive-Behavioral Therapy (CBT)
Trial: 17295573
Drug: Fluoxetine only
RxNorm normalized name: Fluoxetine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine only (Medication-only group)
Trial: 12353189
Drug: Valacyclovir 1000
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1000 mg twice daily for 1 day
Trial: 12353189
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg twice daily for 3 days
Trial: 1574336
Drug: Theophylline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (150 mg/day)
Trial: 3893703
Drug: clebopride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clebopride (0.5 mg TID)
Trial: 24899339
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all control measures
Trial: 19641919
Drug: Intravenous temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous temozolomide (150 mg/m2 as a 90-min infusion)
Trial: 19641919
Drug: Oral temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral temozolomide (200 mg/m2 on days 1, 2, and 5; 150 mg/m2 on days 3 and 4)
Trial: 18593390
Drug: Standard moist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard moist wound-care therapy
Trial: 12568976
Drug: 600 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/die valerian extract LI 156 (Sedonium)
Trial: 12568976
Drug: 10 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/die oxazepam
Trial: 9780763
Drug: 3‐in‐1 block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐in‐1 block with 40 mL of 1.5% mepivacaine (T group, n = 20)
Trial: 9780763
Drug: Subarachnoid puncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid puncture with 3 mL of 2% lidocaine (S group, n = 20)
Trial: 7932518
Drug: Lisinopril (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20-40 mg daily)
Trial: 7932518
Drug: Diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem SR (120-180 mg twice daily)
Trial: 3219879
Drug: Combination inhaler
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination inhaler of salbutamol (800 micrograms) and beclomethasone dipropionate (400 micrograms)
Trial: 29330194
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl 250 mg tid
Trial: 29330194
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl 500 mg tid
Trial: 26756383
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of a dexamethasone implant (IVI‐DEX) after switching from bevacizumab (AD group)
Trial: 26756383
Drug: Bevacizumab followed
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab followed by intravitreal injection of a dexamethasone implant (DA group)
Trial: 25316130
Drug: Pirfenidone therapy
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone therapy (600 mg/day for 8 weeks) with add-on rikkunshi-to from week 4
Trial: 25316130
Drug: Pirfenidone therapy
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone therapy (1200 mg/day)
Trial: 23508526
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal system (≤ 16 mg/24 h)
Trial: 18259028
Drug: 17beta‐estradiol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol (1 mg/d)
Trial: 18259028
Drug: Enalaprilat (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (0.33 microg/min/100 mL forearm volume)
Trial: 10958090
Drug: Unilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Trial: 10958090
Drug: Bilateral spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Trial: 8449845
Drug: Perioperative antibiotic
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotic prophylaxis (cephalosporins used in 86% of cases)
Trial: 29237204
Drug: Aggressive intravenous
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive intravenous hydration with lactated Ringer's solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Trial: 29237204
Drug: Aggressive intravenous
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive intravenous hydration with normal saline solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Trial: 29237204
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous hydration with lactated Ringer's solution (1.5 mL/kg/h during and for 8 hours after ERCP)
Trial: 22281609
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg emodin
Trial: 22281609
Drug: 700 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg/kg vitamin C (Vc)
Trial: 22281609
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg emodin + 700 mg/kg vitamin C (Vc)
Trial: 22281609
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basal diet with 50.3 mg/kg Vc)
Trial: 18514746
Drug: Scopolamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.3 mg subcutaneous)
Trial: 18514746
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg oral)
Trial: 12734150
Drug: CSL 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL 1.5 mL.kg(‐1) per hour fasting duration
Trial: 12734150
Drug: CSL 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL 1.5 mL.kg(‐1) per hour fasting duration with 0.5 g.kg(‐1) dextrose added
Trial: 26773557
Drug: IDegAspSimple titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegAspSimple titration algorithm
Trial: 26773557
Drug: IDegAspStepwise titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDegAspStepwise titration algorithm
Trial: 26093487
Drug: Effect-site remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect-site remifentanil concentration before bolus administration
Trial: 23216875
Drug: Low effect-site
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low effect-site concentration of propofol (1.5-2.5 μg/mL)
Trial: 23216875
Drug: High effect-site
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High effect-site concentration of propofol (3.0-4.0 μg/mL)
Trial: 16601984
Drug: Anti-inflammatory drug
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory drug for 2 weeks
Trial: 16601984
Drug: No anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-inflammatory drug (control)
Trial: 14562669
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker therapy
Trial: 14562669
Drug: No beta
RxNorm normalized name: Amidino beta-alanine
DrugBank: Ompenaclid (DB18819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta blocker therapy (Control)
Trial: 1476277
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of 1 mg.kg‐1 of morphine (group 2)
Trial: 1476277
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of 2 mg.kg‐1 of morphine (group 3)
Trial: 1476277
Drug: i.v. boluses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. boluses of 2 mg of morphine (group 1)
Trial: 6144620
Drug: Nitrefazole 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrefazole 800 mg (4 capsules of 200 mg)
Trial: 6144620
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules of identical appearance)
Trial: 28482641
Drug: Bryostatin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryostatin (25 μg/m2)
Trial: 18279623
Drug: Ropivacaine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine and morphine through thoracic epidural preoperatively (group PE)
Trial: 18279623
Drug: Ropivacaine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine and morphine through thoracic epidural postoperatively (group E)
Trial: 18279623
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of fentanyl postoperatively (group IV)
Trial: 8955966
Drug: Intramuscular clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular clonidine (300 micrograms)